These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 11846622)

  • 21. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients.
    Ragueneau-Majlessi I; Levy RH; Bergen D; Garnett W; Rosenfeld W; Mather G; Shah J; Grundy JS
    Epilepsy Res; 2004 Nov; 62(1):1-11. PubMed ID: 15519127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison between the Cobas Integra immunoassay and high-performance liquid chromatography for therapeutic monitoring of carbamazepine.
    Hermida J; Bóveda MD; Vadillo FJ; Tutor JC
    Clin Biochem; 2002 May; 35(3):251-4. PubMed ID: 12074835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of CYP3A5 and UGT2B7 variants on steady-state carbamazepine concentrations in Chinese epileptic patients.
    Lu Q; Huang YT; Shu Y; Xu P; Xiang DX; Qu Q; Qu J
    Medicine (Baltimore); 2018 Jul; 97(30):e11662. PubMed ID: 30045320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy.
    Ahmed GF; Brundage RC; Marino SE; Cloyd JC; Leppik IE; Pennell PB; Ramsay RE; Birnbaum AK
    J Clin Pharmacol; 2013 Mar; 53(3):276-84. PubMed ID: 23408495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy.
    Rivas N; Buelga DS; Elger CE; Santos-Borbujo J; Otero MJ; Domínguez-Gil A; García MJ
    Ther Drug Monit; 2008 Aug; 30(4):483-9. PubMed ID: 18641550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine.
    Miller AD; Krauss GL; Hamzeh FM
    Acta Neurol Scand; 2004 Jun; 109(6):374-7. PubMed ID: 15147458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and cognitive effects of carbamazepine formulations with different dissolution rates.
    Aldenkamp AP; Rentmeester T; Hulsman J; Majoie M; Doelman J; Diepman L; Schellekens A; Franken M; Olling M
    Eur J Clin Pharmacol; 1998 Apr; 54(2):185-92. PubMed ID: 9626926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pharmacodynamic approach to the estimate of carbamazepine autoinduction.
    Scheyer RD; Cramer JA; Mattson RH
    J Pharm Sci; 1994 Apr; 83(4):491-4. PubMed ID: 8046601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on dose-adjusted plasma levels of carbamazepine in epileptic patients in South Indian population.
    Ganesapandian M; Ramasamy K; Adithan S; Narayan SK
    Indian J Pharmacol; 2019; 51(6):384-388. PubMed ID: 32029960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of valproate in Chinese children with epilepsy.
    Jiang DC; Wang L; Wang YQ; Li L; Lu W; Bai XR
    Acta Pharmacol Sin; 2007 Oct; 28(10):1677-84. PubMed ID: 17883957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults.
    Chien S; Bialer M; Solanki B; Verhaeghe T; Doose DR; Novak G; Yao C
    Epilepsia; 2006 Nov; 47(11):1830-40. PubMed ID: 17116022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients.
    Park PW; Seo YH; Ahn JY; Kim KA; Park JY
    J Clin Pharm Ther; 2009 Oct; 34(5):569-74. PubMed ID: 19744012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of caffeine on pharmacokinetic profile of sodium valproate and carbamazepine in normal human volunteers.
    Vaz J; Kulkarni C; David J; Joseph T
    Indian J Exp Biol; 1998 Jan; 36(1):112-4. PubMed ID: 9536660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for carbamazepine elevation and toxicity following epilepsy surgery.
    Hiremath GK; Kotagal P; Bingaman W; Hovinga C; Wyllie E; Morris H; Nelson D
    Seizure; 2005 Jul; 14(5):312-7. PubMed ID: 15876544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of treatment and additional disease on pharmacokinetic of valproic acid in children with epilepsy.
    Juárez-Olguín H; Lugo-Goytia G; Flores-Murrieta F; Ruiz-García M; Lares Asseff I; Flores Pérez J
    Rev Invest Clin; 2010; 62(6):516-23. PubMed ID: 21416779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment.
    Moreno J; Belmont A; Jaimes O; Santos JA; López G; Campos MG; Amancio O; Pérez P; Heinze G
    Arch Med Res; 2004; 35(2):168-71. PubMed ID: 15010199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations.
    Ahmad A; Garnett WR
    Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An experimental design for finding of minimum dosage of carbamazepine and valproate in preventing of seizure attacks.
    Samaei A; Nobahar M; Vafaei AA
    Pak J Pharm Sci; 2009 Apr; 22(2):180-3. PubMed ID: 19339229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Therapeutic drug monitoring and the pharmacokinetics of carbamazepine in children with a convulsive syndrome].
    Kholodov LE; Prityko AG; Ivanova ES; Sokolov AV; Tishchenkova IF; Dubrovina LIu; Postnikov SS; Tatarinov PA; Kopanev IuA; Veselov NK
    Zh Nevrol Psikhiatr Im S S Korsakova; 1995; 95(3):35-40. PubMed ID: 7571921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steady state pharmacokinetics of carbamazepine-phenobarbital interaction in patients with epilepsy.
    Sennoune S; Iliadis A; Bonneton J; Barra Y; Genton P; Mesdjian E
    Biopharm Drug Dispos; 1996 Mar; 17(2):155-64. PubMed ID: 8907722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.